Skip to content
    BrightEdge logo

    BrightEdge

    Atlanta, Georgia, United StatesFounded 2019

    BrightEdge is the donor-funded innovation, impact investment, and venture capital arm of the American Cancer Society. It invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, medical devices, and technologies to advance the ACS mission to eradicate cancer.

    38% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $44.3M (across 27 rounds with reported amounts).

    Find people at BrightEdge on Goldilocks AI

    Portfolio

    22

    Fund Size

    $80.3M

    Top Stage

    Seed

    Last 12 Mo

    0

    Team

    Steve Curtis,PhD

    Steve Curtis,PhD

    Managing Director

    Barbra Kocsis,MBA, MA

    Barbra Kocsis,MBA, MA

    Director, Operations

    Farnaz Bakhshi,PhD

    Farnaz Bakhshi,PhD

    Director, Innovation

    Amy Berg

    Amy Berg

    Principal, Philanthropy

    Michka Sharpe,PhD

    Michka Sharpe,PhD

    Senior Associate, Investments

    Jess Miciak,PhD

    Jess Miciak,PhD

    Associate, Investments

    Calum Daly

    Calum Daly

    Investment Fund and Business Analyst

    Nate Macht,MBA

    Nate Macht,MBA

    Investment and Innovation Senior Analyst

    Ana Rojas

    Ana Rojas

    Executive Assistant

    Bianca Scimemi

    Bianca Scimemi

    Entrepreneurs Program Manager

    Carolyn Simmons

    Carolyn Simmons

    Operations and Events Coordinator

    Josh Zail

    Josh Zail

    Impact Program Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    29 investments
    CompanyRoundAmountDate
    Alpheus Medical logoAlpheus MedicalSeries B$52MMay 2025
    AAlpheusSeries B$52MMay 2025
    Alpheus Medical logoAlpheus MedicalSeries A$52MMay 2025
    CellCentric logoCellCentricSeries C$120MJan 2025
    AAlpheusSeries B$52MJan 2025
    Alpheus Medical logoAlpheus MedicalSeries B$52MJan 2025
    TippingPoint Biosciences logoTippingPoint BiosciencesPre-Seed$2.5MSep 2024
    MModifi BiosciencesSeed$4.3MOct 2023
    MODIFI logoMODIFISeed$4.3MOct 2023
    Modifi Bio logoModifi BioSeed$4.3MOct 2023
    Thatch logoThatchSeed$6MFeb 2023
    Meliora Therapeutics logoMeliora TherapeuticsSeed$11MSep 2022
    Auron Therapeutics logoAuron TherapeuticsSeries A$48MJul 2022
    Meliora Therapeutics logoMeliora TherapeuticsSeed$11MJan 2022
    Immunitas Therapeutics logoImmunitas TherapeuticsSeries B$58MAug 2021
    IImmunitasSeries B$58MAug 2021
    Interius BioTherapeutics logoInterius BioTherapeuticsSeries A$76MMay 2021
    IImmunitasSeries B$58MJan 2021
    Interius BioTherapeutics logoInterius BioTherapeuticsSeries A$76MJan 2021
    Tmunity logoTmunitySeries B$75MOct 2019
    Freenome logoFreenomeSeries C$160MJul 2019
    Navigating Cancer logoNavigating CancerSeries D$10MAug 2015
    TailorMed logoTailorMedUnknown$40M—
    CCheckmate PharmaceuticalsSeries C$85M—
    Signify Bio logoSignify BioUnknown$15M—
    Page 1 of 2

    Top Co-Investors

    Last updated: 20 October 2026